Table of Contents
<< Previous Issue | Jan 2009 (Vol: 2009, Issue: 1) | Next Issue >> |
- Section: Business Commentaries
-
How to Survive in Tough Economic Times
- Section: Joint Venture
-
Teva’s Biosimilar Capabilities Mount with its Latest Joint Venture
- Section: Licensing
-
Wyeth Deals Signal Diversification Strategy
-
ZymoGenetics in Blockbuster Deal with BMS
-
S*Bio Signs Two Major Anticancer Deals
- Section: Mergers & Acquisitions
-
Endo Diversification Leads to Indevus Buyout
-
Wyeth Acquisition Could be Major Distraction for Pfizer
-
Pfizer Swallows Wyeth - Could Spark Other Acquisitions
-
Astellas Bids US$1 B for CV Therapeutics
-
Roche Gets Hostile with Genentech